Persbericht Innovatieve reuma-scanner gaat internationaal 28 augustus 2017 (Dutch)

Medtech startup Hemics verkoopt eerste HandScan-systemen over de grens

De Nederlandse medisch-technologische innovatie ‘HandScan’ wordt deze maand voor het eerst in het buitenland in gebruik genomen. Klinieken in Duitsland en België hebben de innovatieve reuma-scanner van de Eindhovense start-up Hemics aangeschaft. Voor Hemics is dit een belangrijke stap naar haar doel, om ook internationaal een verschil te maken in het leven van veel reumatoïde artritis (RA-) patiënten.

Lees verder

Press release Dutch innovative rheumatism scanner on the rise August 28, 2017

Medtech start-up Hemics sells first HandScan systems internationally

The HandScan, a Dutch medical technology innovation, will be used this month for the first time outside the Netherlands. Clinics in Germany and Belgium have purchased the innovative rheumatism scanner from Eindhoven start-up company Hemics. This marks an important step for Hemics towards its goal of making a difference internationally as well as nationally in the life of many patients who suffer from rheumatoid arthritis (RA).

Read more

Press release Máxima Medisch Centrum January 10, 2017 (Dutch)

MMC biedt als allereerste pijnloze controle voor artritispatiënten

Reumatoïde artritispatiënten worden vanaf nu pijnloos onderzocht op ontstekingen dankzij een HandScan. De objectieve metingen van dit apparaat kunnen bovendien leiden tot een betere bijstelling van vaak kostbare medicatie. Máxima Medisch Centrum (MMC) neemt de HandScan als eerste ziekenhuis ter wereld in gebruik in de dagelijkse praktijk.

Lees verder

Press release September 16, 2015

Pan-European APPROACH project receives 15 million Euro research funding to find the right osteoarthritis medicine for the right patient

In a bid to stimulate the development of much needed treatments for osteoarthritis, a consortium of 24 partners comprising pharmaceutical companies, biotech companies, academic institutions, not-for-profit organizations, small and medium enterprises (SMEs) and public bodies have joined forces in the pan-European APPROACH (Applied Public-Private Research enabling OsteoArthritis Clinical Headway) project, with total research funding of 15 million Euros. Of this amount, 7.5 million Euros will come from the European Innovative Medicines Initiative (IMI) and 7.5 million Euros in the form of ‘in kind’ contributions from participating members of the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Read more

Press release January 9, 2015

Hemics receives required CE marking and closes B-round financing to market the HandScan

Hemics BV received CE marking required for commercial sales of its medical device the HandScan and  closed a new investment round, welcoming new investor DFZ Participaties, a subsidiary of health insurance company De Friesland. Existing investors Thuja Capital, Point One Innovation Fund, and the Brabant Development Agency (BOM) also participated. The investment will enable Hemics to further develop, clinically test and market the HandScan, an optical imaging device to monitor joint inflammation in hands and wrists of Rheumatoid Arthritis (RA) patients.

Read more

Persbericht 9 januari 2015

Hemics verkrijgt vereiste CE markering en sluit serie B-financieringsronde om de HandScan te vermarkten

Hemics BV heeft CE markering verkregen, vereist voor commerciële verkoop van haar medisch product de HandScan, en heeft haar tweede financieringsronde succesvol afgerond. Nieuw toegetreden is DFZ Participaties, een dochter van De Friesland Zorgverzekeraar. Bestaande investeerders Thuja Capital, Point One Innovation Fund en de Brabantse Ontwikkelings Maatschappij (BOM) hebben ook deelgenomen aan de B-ronde. Hemics gaat de investering gebruiken voor verdere ontwikkeling, klinische studies, en het naar de markt brengen van de HandScan, een optisch beeldvormend apparaat om ontsteking in hand- en polsgewrichten te visualiseren bij patienten met reumatoïde artritis.

Lees verder

Press release March 31, 2014

Cost effectiveness and efficacy of the Hemics HandScan will be studied in multi-center tight control treatment of Rheumatoid Arthritis.

Hemics BV announces today a multi-center clinical study to evaluate the cost effectiveness and efficacy of its HandScan in tight control treatment of Rheumatoid Arthritis (RA). The study will be performed at the University Medical Center (UMC) Utrecht and four general hospitals in the same region, partners of the SRU (Stichting Reumaonderzoek Utrecht), in collaboration with the Dutch Arthritis Foundation and Hemics. In an earlier study in UMC Utrecht using Ultrasound (US) measurements as gold standard, a prototype of the HandScan showed superior performance in detecting joint inflammation when compared to clinical examination, suggesting that HandScan is a better tool for monitoring rheumatoid arthritis. The present study will determine whether this is indeed the case.

Read more

Persbericht 31 maart 2014

Ontsteking pijnloos meten met licht: Groot Nederlands onderzoek naar betere controle reuma

Binnenkort start een Nederlandse studie waarin de kosteneffectiviteit en doeltreffendheid wordt onderzocht van de HandScan, een optisch apparaat waarmee het verloop van reumatoïde artritis mogelijk beter kan worden gevolgd.

Lees verder

Press release April 22, 2013

Hemics and DEMCON start HandScan development, the first non-invasive imaging system for monitoring inflammatory status of Rheumatoid Arthritis patients

Hemics BV and Demcon Advanced Mechatronics BV announce that they have started developing the HandScan into a commercial product. This non-invasive imaging system was developed by Hemics for monitoring the inflammatory status of Rheumatoid Arthritis (“RA”) patients. As part of the collaboration, DEMCON will be responsible for systems engineering, electronics, mechanics, optics and embedded software, while Hemics will remain in charge of the data algorithm, which translates the measurement results from the scanner into clinical information for rheumatologists. The two partners are facing the challenge of designing a lightweight, compact, easy-to-use and affordable device. Given that rheumatologists have to accept the device as part of their daily work, it is not only the illumination module that requires special attention, but the intuitive user interface and the industrial design as well.
Read more

Press release April 5, 2013

Akeso Medical Imaging renamed Hemics.  

Akeso Medical Imaging BV announces today that as of this day the company has adopted a new name: Hemics BV. Hemics is the first company in the world to develop a non invasive optical imaging device that supports the rheumatologist in objective assessment of inflammatory status in RA. Inflammatory status is a key parameter for rheumatologists in treatment decisions for patients with RA. Reducing the inflammation to a state of remission will improve quality of life of RA patients and reduce long term disability. The device works by measuring the blood flow in 22 joints of the hands and wrists using diffuse optical transmission in combination with a patented blood flow modulation method. Based on optical technology the device poses no risk for the patient and is fast, operator independent, inexpensive and easy to use.
Read more

Press Release March 1, 2012.
Akeso Medical Imaging starts clinical study for proof of concept of imaging device for rheumatoid arthritis disease activity monitoring and control.

Akeso Medical Imaging BV, announces today the start of a clinical study with their novel imaging device for assessment of joint inflammation in patient with rheumatoid arthritis (RA). In this proof of concept study, Akeso’s imaging device will be compared to other methods to assess disease status, such as the DAS-28 score, Ultrasound and in some cases MRI. The study will be performed at the University Medical Center Utrecht (UMC Utrecht) in cooperation with Regional Rheumatology Centre Eindhoven (RRC). Seventy subjects will be included; sixty RA patients with varying degrees of inflammation of the joints of hands and wrists at the time of examination and a control group of ten subjects.
Read more

Press Release September 20, 2011.
Akeso Medical Imaging closes its first financing round to develop an imaging device for rheumatoid arthritis disease activity monitoring and control.

Akeso Medical Imaging BV, a spin-off from Philips Research, announces today the closure of its first financing round led by Thuja Capital Healthcare Seed Fund with additional financing from the Brabant Spin-Off Fund and Point-One Innovation Fund. Philips will be a minority shareholder of Akeso Medical Imaging as a result of its contribution to the development of Akeso’s innovative Rheumatoid Arthritis (RA) imaging system. The funds will be used to further develop the imaging system and software, its clinical validation and for obtaining regulatory approval in Europe.

Read more